TNF Pharmaceuticals Inc (TNFA) Quote

TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development

Machine learning technology used to identify patients for studies of muscle mass preservation during GLP-1 treatment TNF Pharmaceuticals, Inc...

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025

Positive clinical data validates commencement of a larger Phase 2b clinical trial in elderly patients post-hip fracture Drug shown to decrease...

Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405

Form 8-K - Current report

TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia

Positive clinical data validates current Phase 2b clinical trial of isomyosamine as a treatment for chronic inflammation associated with muscle...